Dr. Yafit Stark, Chairperson of the Board
Dr. Stark is Vice President at Teva Pharmaceutical Industries. Ltd. Chief Clinical Officer and Head of Oncology, Emerging Therapeutic Areas and Biogenerics Innovative R&D, Dr. Stark joined Teva in 1987, from 1991 to 1994 she was based in the US, where she established the Innovative R&D Division of Teva USA and was responsible for the clinical development of Copaxone®. Dr. Stark then established and managed the Innovative R&D Division’s global clinical research and clinical development of all innovative products at Teva. Dr. Stark holds a Ph.D. degree in Pathology from the Sackler School of Medicine, Tel Aviv University, and a Post-Doctorate in Immuno-Histopathology from Tel Aviv University and the Weizmann Institute of Science. She served as a member of the academic staff of the Sackler School of Medicine and continues to lecture on Pathology and Oncology Drug Development in the School of Medicine’s College for Advanced Degrees. Dr. Stark is a member of the Nominating/Elections Committee of the Association of Clinical Research Professionals.
Dr. Daphne Haim-Langford, Director
Dr. Daphne Haim-Langford has over 16 years of managerial experience. Dr. Haim-Langford has been involved in medical device entrepreneurship and specializes in fundraising, strategic planning, marketing, distribution, reimbursement, and product management in the medical device industry. Dr. Haim-Langford is the Chairperson of the Israeli Biomimicry Organization, a nonprofit organization promoting sustainable innovation inspired by nature. She is also a lecturer at the Interdisciplinary Center (IDC) Herzliya, and holds a PhD degree in Biotechnology from the Technion and a B.Sc. in Nutrition from Hebrew University (Cum Laude). Prior to joining Xenia Dr. Haim-Langford acted as VP Business Development & Marketing at Medingo, an insulin patch pump company which was acquired by Roche, General Manager with PerAssist, a Misgav Technology Center portfolio company and was the Product Manager for Carmel Biosensor, developing biosensors for glucose and anesthesia.
Rekad Kheredin, Co-founder & Director
Mr. Rekad Kheredin Graduated and received an engineer degree from the Technion, MA degree from the Faculty of Social Sciences of Tel Aviv University and in addition he graduated a directors course from Haifa University. Mr. Kheredin holds the Chairman position at the School of Sciences for Outstanding Druses, he founded the Space-Center for youngsters and is a Lieutenant Colonel (reserve) in the IDF. Prior to Omnix Medical Mr. Kheredin held many senior managerial positions including the mayor of Hurfesh, CEO of Ziv water-cooperation, and a board member in many public institutions in Israel. As of today, Mr. Kheredin is the CEO of Maxima-Hazafon cooperation, a Board member at ELTA Systems Ltd, and is the Vice Chairman of the National Road Safety Authority.
Ori Chochen, Director
Ori Choshen is the CEO of VLX Ventures. Ori Choshen has 15 years of experience in management, business development, marketing, entrepreneurship and VC, mainly in areas of SW & IT. He holds an LL.B degree (Law), a B.A. degree in Philosophy (Cum Laude) from Tel Aviv University, and an MBA (Cum Laude) from the Solvay Business School in Brussels, Belgium. Prior to joining VLX Ventures in 2013 Ori was VP Business Development of Xenia VC. Co-founder of Aniba, the first local web-site in the event planning category. Director of Business Development with SanDisk where he managed the Eco-System group. Ori joined SanDisk as part of the company’s $1.6B acquisition of M-Systems in 2006. Director of Business Development and Marketing at M-Systems. Mr. Choshen managed the Terminal Equipment Department at the marketing division of Orange Israel, and was a member in Hutchison’s global handset group. Mr. Choshen Served 3 years as an Investment Manager in PFC, Orange’s VC subsidiary.